Left atrial appendage closure with a new occluder device: efficacy, safety and mid-term performance

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Llagostera Martín, Marc
• dc.contributor.author Cubero Gallego, Héctor
• dc.contributor.author Mas Stachurska, Aleksandra
• dc.contributor.author Salvatella Giralt, Neus
• dc.contributor.author Sánchez Carpintero, Andrea
• dc.contributor.author Tizón-Marcos, Helena
• dc.contributor.author Garcia Guimaraes, Marcos
• dc.contributor.author Calvo-Fernández, Alicia
• dc.contributor.author Molina Ferragut, Luis
• dc.contributor.author Vaquerizo Montilla, Beatriz
• dc.date.accessioned 2021-09-29T06:38:23Z
• dc.date.available 2021-09-29T06:38:23Z
• dc.date.issued 2021
• dc.description.abstract The LAmbreTM device is a novel system designed for left atrial appendage closure (LAAC). First registries showed a high rate of device implantation success. However, few mid-term results are available. We present our 1- and 12-month follow-up results for this device. This prospective, single-center registry included consecutive patients with nonvalvular atrial fibrillation who underwent LAAC with the LAmbreTM device. Transesophageal echocardiography (TEE) was performed at 1-month follow-up. In total, 55 patients were included. The population was elderly (75 ± 9.4 years), with a high proportion of comorbidities. The mean CHA2DS2-VASc and HAS-BLED scores were 4.6 ± 1.6 and 3.9 ± 1.0, respectively. Previous history of a major bleeding event was present in 37 patients (67.3%). Procedural success was achieved in 54 patients (98.2%). Device success was achieved in 100% of patients in whom device implantation was attempted (54 patients). Major in-hospital device-related complications included mortality of one patient (1.8%) and pericardial tamponade in two patients (3.6%); the incidence of stroke was 0%. No thrombus or significant leaks (≥5 mm) were observed on 1-month TEE. At 12 months, adverse events were overall death (1.8%), transient ischemic attack/ischemic stroke (1.8%), and major bleeding events (Bleeding Academic Research Consortium (BARC) 3a and 3c; 11%). In this high-risk population, the LAmbreTM device seems to be a safe and effective option for LAAC with a remarkable mid-term performance.
• dc.format.mimetype application/pdf
• dc.identifier.citation Llagostera-Martín M, Cubero-Gallego H, Mas-Stachurska A, Salvatella N, Sánchez-Carpintero A, Tizon-Marcos H, Garcia-Guimaraes M, Calvo-Fernandez A, Molina L, Vaquerizo B. Left atrial appendage closure with a new occluder device: efficacy, safety and mid-term performance. J Clin Med. 2021;10(7):1421. DOI: 10.3390/jcm10071421
• dc.identifier.doi http://dx.doi.org/10.3390/jcm10071421
• dc.identifier.issn 2077-0383
• dc.identifier.uri http://hdl.handle.net/10230/48526
• dc.language.iso eng
• dc.publisher MDPI
• dc.relation.ispartof J Clin Med. 2021;10(7):1421
• dc.rights © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword LAmbre
• dc.subject.keyword Atrial fibrillation
• dc.subject.keyword Left atrial appendage closure
• dc.subject.keyword Stroke
• dc.title Left atrial appendage closure with a new occluder device: efficacy, safety and mid-term performance
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion